Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

EGFR tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harboring activating mutations in the EGFR kinase(1,2), but resistance arises rapidly, most frequently due to the secondary T790M mutation within the ATP-site of the recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Yong, Yun, Cai-Hong, Park, Eunyoung, Ercan, Dalia, Manuia, Mari, Juarez, Jose, Xu, Chunxiao, Rhee, Kevin, Chen, Ting, Zhang, Haikuo, Palakurthi, Sangeetha, Jang, Jaebong, Lelais, Gerald, DiDonato, Michael, Bursulaya, Badry, Michellys, Pierre-Yves, Epple, Robert, Marsilje, Thomas H., McNeill, Matthew, Lu, Wenshuo, Harris, Jennifer, Bender, Steven, Wong, Kwok-Kin, Jänne, Pasi A., Eck, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929832/
https://www.ncbi.nlm.nih.gov/pubmed/27251290
http://dx.doi.org/10.1038/nature17960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929832/
https://www.ncbi.nlm.nih.gov/pubmed/27251290
http://dx.doi.org/10.1038/nature17960

Ejemplares similares